Cargando…

(18)F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy

The ability to assess the distribution and extent of tau pathology in Alzheimer’s disease and progressive supranuclear palsy in vivo would help to develop biomarkers for these tauopathies and clinical trials of disease-modifying therapies. New radioligands for positron emission tomography have gener...

Descripción completa

Detalles Bibliográficos
Autores principales:	Passamonti, Luca, Vázquez Rodríguez, Patricia, Hong, Young T., Allinson, Kieren S. J., Williamson, David, Borchert, Robin J., Sami, Saber, Cope, Thomas E., Bevan-Jones, W. Richard, Jones, P. Simon, Arnold, Robert, Surendranathan, Ajenthan, Mak, Elijah, Su, Li, Fryer, Tim D., Aigbirhio, Franklin I., O’Brien, John T., Rowe, James B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382948/ https://www.ncbi.nlm.nih.gov/pubmed/28122879 http://dx.doi.org/10.1093/brain/aww340

Ejemplares similares

Imaging tau burden in dementia with Lewy bodies using [(18)F]-AV1451 positron emission tomography
por: Mak, Elijah, et al.
Publicado: (2021)

[(11)C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy
por: Passamonti, Luca, et al.
Publicado: (2018)

(18)F-AV1451 PET imaging and multimodal MRI changes in progressive supranuclear palsy
por: Nicastro, Nicolas, et al.
Publicado: (2019)

[(18)F]AV‐1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation
por: Bevan Jones, W. Richard, et al.
Publicado: (2016)

[(18)F]-AV-1451 binding in the substantia nigra as a marker of neuromelanin in Lewy body diseases
por: Mak, Elijah, et al.
Publicado: (2021)

[(18)F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia
por: Bevan-Jones, W R, et al.
Publicado: (2018)

[(18)F]AV‐1451 binding is increased in frontotemporal dementia due to C9orf72 expansion
por: Bevan‐Jones, Richard W., et al.
Publicado: (2018)

Molecular pathology and synaptic loss in primary tauopathies: an (18)F-AV-1451 and (11)C-UCB-J PET study
por: Holland, Negin, et al.
Publicado: (2021)

Tau burden and the functional connectome in Alzheimer’s disease and progressive supranuclear palsy
por: Cope, Thomas E, et al.
Publicado: (2018)

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy
por: Smith, Ruben, et al.
Publicado: (2016)

Increased basal ganglia binding of (18) F‐AV‐1451 in patients with progressive supranuclear palsy
por: Smith, Ruben, et al.
Publicado: (2016)

In Vivo (18)F-Flortaucipir PET Does Not Accurately Support the Staging of Progressive Supranuclear Palsy
por: Malpetti, Maura, et al.
Publicado: (2022)

Structural correlates of survival in Progressive Supranuclear Palsy
por: Street, Duncan, et al.
Publicado: (2023)

Neuroinflammation predicts disease progression in progressive supranuclear palsy
por: Malpetti, Maura, et al.
Publicado: (2021)

AV‐1451 tau and β‐amyloid positron emission tomography imaging in dementia with Lewy bodies
por: Kantarci, Kejal, et al.
Publicado: (2016)

Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses
por: Bevan-Jones, W Richard, et al.
Publicado: (2017)

Early microglial activation and peripheral inflammation in dementia with Lewy bodies
por: Surendranathan, Ajenthan, et al.
Publicado: (2018)

Correlation of microglial activation with white matter changes in dementia with Lewy bodies
por: Nicastro, Nicolas, et al.
Publicado: (2020)

An autoradiographic evaluation of AV-1451 Tau PET in dementia
por: Lowe, Val J., et al.
Publicado: (2016)

Locus coeruleus pathology in progressive supranuclear palsy, and its relation to disease severity
por: Kaalund, Sanne Simone, et al.
Publicado: (2020)

Validation of the new pathology staging system for progressive supranuclear palsy
por: Briggs, Mayen, et al.
Publicado: (2021)

In vivo retention of (18)F-AV-1451 in corticobasal syndrome
por: Smith, Ruben, et al.
Publicado: (2017)

Increased Uptake of AV-1451 in a Subacute Infarction Lesion
por: Cho, Soo Hyun, et al.
Publicado: (2018)

Brain network alterations in individuals with and without mild cognitive impairment: parallel independent component analysis of AV1451 and AV45 positron emission tomography
por: Li, Yuan, et al.
Publicado: (2019)

(11)C‐PK11195 PET imaging and white matter changes in Parkinson’s disease dementia
por: Nicastro, Nicolas, et al.
Publicado: (2019)

Multi-modal MRI investigation of volumetric and microstructural changes in the hippocampus and its subfields in mild cognitive impairment, Alzheimer's disease, and dementia with Lewy bodies
por: Mak, Elijah, et al.
Publicado: (2017)

Speaker 1: John O’Brien, UK
por: O’Brien, John T, et al.
Publicado: (2016)

Quantification of Tau Load Using [(18)F]AV1451 PET
por: Golla, Sandeep S. V., et al.
Publicado: (2017)

An updated radiosynthesis of [(18)F]AV1451 for tau PET imaging
por: Mossine, Andrew V., et al.
Publicado: (2017)

The Role of 18F-Flortaucipir (AV-1451) in the Diagnosis of Neurodegenerative Disorders
por: Roy, Saswata, et al.
Publicado: (2021)

In vivo coupling of tau pathology and cortical thinning in Alzheimer's disease
por: Mak, Elijah, et al.
Publicado: (2018)

Falls in Progressive Supranuclear Palsy
por: Brown, Fraser S., et al.
Publicado: (2019)

Neurophysiological consequences of synapse loss in progressive supranuclear palsy
por: Adams, Natalie E, et al.
Publicado: (2022)

Deep learning application for the classification of Alzheimer’s disease using (18)F-flortaucipir (AV-1451) tau positron emission tomography
por: Park, Sang Won, et al.
Publicado: (2023)

Altered structural connectivity networks in dementia with lewy bodies
por: Nicastro, Nicolas, et al.
Publicado: (2021)

(18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
por: Tsai, Richard M., et al.
Publicado: (2019)

Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum
por: Bevan-Jones, W Richard, et al.
Publicado: (2020)

(18)F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies
por: Smith, Ruben, et al.
Publicado: (2018)

(18)F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Imaging Aβ and tau in early stage Alzheimer’s disease with [(18)F]AV45 and [(18)F]AV1451
por: Firouzian, Azadeh, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_uidagdbknrs2v1a6veac6ac2bn